ARCHIVES

High Dose Chemotherapy Significantly Prolongs Survival In ECOG Clinical Trial

This article is from The Cancer Letter archive.

Vol. 31 No. 11 | November 28, 2008

Download PDF Visit The Full Archive

Related Articles

ODAC votes 9-6 in favor of Clolar for pediatric acute lymphoblastic leukemia, but votes against Marqibo for non-Hodgkin’s lymphoma.

December 10, 2004

ACS Adopts Principles As Basis For Reform Of Health Care System

July 17, 1992

Inhibitor Reduces Spleen Size By 35 Percent or More in Phase III

June 28, 2013

In Brief: HEW Clamps Down On Former Employees Hired To Go After Jobs They Had Helped Develop

May 3, 1974

Breast Cancer Working Group Lists Research Needed

July 1, 1988

NHIS Cancer Control Supplement To Survey 52,000

October 4, 1985